280 related articles for article (PubMed ID: 34023508)
1. Generation of highly proliferative, rejuvenated cytotoxic T cell clones through pluripotency reprogramming for adoptive immunotherapy.
Kawai Y; Kawana-Tachikawa A; Kitayama S; Ueda T; Miki S; Watanabe A; Kaneko S
Mol Ther; 2021 Oct; 29(10):3027-3041. PubMed ID: 34023508
[TBL] [Abstract][Full Text] [Related]
2. Sustainable Antiviral Efficacy of Rejuvenated HIV-Specific Cytotoxic T Lymphocytes Generated from Induced Pluripotent Stem Cells.
Miki S; Kawai Y; Nakayama-Hosoya K; Iwabuchi R; Terahara K; Tsunetsugu-Yokota Y; Koga M; Matano T; Kaneko S; Kawana-Tachikawa A
J Virol; 2022 Mar; 96(6):e0221721. PubMed ID: 35107374
[TBL] [Abstract][Full Text] [Related]
3. Redifferentiation of Adaptive Naïve-Like CTL from T-Cell-Derived iPSC.
Kawai Y; Kaneko S
Methods Mol Biol; 2019; 2048():71-75. PubMed ID: 31396930
[TBL] [Abstract][Full Text] [Related]
4. Differentiating CD8αβ T Cells from TCR-Transduced iPSCs for Cancer Immunotherapy.
Minagawa A; Kaneko S
Methods Mol Biol; 2019; 2048():81-84. PubMed ID: 31396932
[TBL] [Abstract][Full Text] [Related]
5. 'Off-the-shelf' immunotherapy with iPSC-derived rejuvenated cytotoxic T lymphocytes.
Ando M; Nakauchi H
Exp Hematol; 2017 Mar; 47():2-12. PubMed ID: 27826124
[TBL] [Abstract][Full Text] [Related]
6. Generation of Pure Highly Functional Human Anti-Tumor Specific Cytotoxic T Lymphocytes With Stem Cell-Like Memory Features for Melanoma Immunotherapy.
Hamieh M; Chatillon JF; Dupel E; Bayeux F; Fauquembergue E; Maby P; Drouet A; Duval-Modeste AB; Adriouch S; Boyer O; Latouche JB
Front Immunol; 2021; 12():674276. PubMed ID: 34566953
[TBL] [Abstract][Full Text] [Related]
7. Generation of induced pluripotent stem cell (iPSC) from NY-ESO-I-specific cytotoxic T cells isolated from the melanoma patient with minor HLAs: The practical pilot study for the adoptive immunotherapy for melanoma using iPSC technology.
Itoh M; Kawagoe S; Nakagawa H; Asahina A; Okano HJ
Exp Dermatol; 2023 Feb; 32(2):126-134. PubMed ID: 36222007
[TBL] [Abstract][Full Text] [Related]
8. Cloning and expansion of antigen-specific T cells using iPS cell technology: development of "off-the-shelf" T cells for the use in allogeneic transfusion settings.
Kawamoto H; Masuda K; Nagano S; Maeda T
Int J Hematol; 2018 Mar; 107(3):271-277. PubMed ID: 29388165
[TBL] [Abstract][Full Text] [Related]
9. Directed differentiation of induced pluripotent stem cells towards T lymphocytes.
Lei F; Haque R; Xiong X; Song J
J Vis Exp; 2012 May; (63):e3986. PubMed ID: 22617911
[TBL] [Abstract][Full Text] [Related]
10. Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αβ+ T cells targeting multiple myeloma.
Bae J; Kitayama S; Herbert Z; Daheron L; Kurata K; Keskin DB; Livak K; Li S; Tarannum M; Romee R; Samur M; Munshi NC; Kaneko S; Ritz J; Anderson KC
Blood; 2024 Mar; 143(10):895-911. PubMed ID: 37890146
[TBL] [Abstract][Full Text] [Related]
11. Human iPSC Generation from Antigen-Specific T Cells.
Nishimura T; Murmann Y; Nakauchi H
Methods Mol Biol; 2019; 2048():53-57. PubMed ID: 31396928
[TBL] [Abstract][Full Text] [Related]
12. Memoirs of a reincarnated T cell.
Crompton JG; Rao M; Restifo NP
Cell Stem Cell; 2013 Jan; 12(1):6-8. PubMed ID: 23290132
[TBL] [Abstract][Full Text] [Related]
13. IL-21-treated naive CD45RA+ CD8+ T cells represent a reliable source for producing leukemia-reactive cytotoxic T lymphocytes with high proliferative potential and early differentiation phenotype.
Albrecht J; Frey M; Teschner D; Carbol A; Theobald M; Herr W; Distler E
Cancer Immunol Immunother; 2011 Feb; 60(2):235-48. PubMed ID: 21046101
[TBL] [Abstract][Full Text] [Related]
14. A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy.
Iriguchi S; Yasui Y; Kawai Y; Arima S; Kunitomo M; Sato T; Ueda T; Minagawa A; Mishima Y; Yanagawa N; Baba Y; Miyake Y; Nakayama K; Takiguchi M; Shinohara T; Nakatsura T; Yasukawa M; Kassai Y; Hayashi A; Kaneko S
Nat Commun; 2021 Jan; 12(1):430. PubMed ID: 33462228
[TBL] [Abstract][Full Text] [Related]
15. Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy.
Minagawa A; Yoshikawa T; Yasukawa M; Hotta A; Kunitomo M; Iriguchi S; Takiguchi M; Kassai Y; Imai E; Yasui Y; Kawai Y; Zhang R; Uemura Y; Miyoshi H; Nakanishi M; Watanabe A; Hayashi A; Kawana K; Fujii T; Nakatsura T; Kaneko S
Cell Stem Cell; 2018 Dec; 23(6):850-858.e4. PubMed ID: 30449714
[TBL] [Abstract][Full Text] [Related]
16. Generation of Tumor Antigen-Specific iPSC-Derived Thymic Emigrants Using a 3D Thymic Culture System.
Vizcardo R; Klemen ND; Islam SMR; Gurusamy D; Tamaoki N; Yamada D; Koseki H; Kidder BL; Yu Z; Jia L; Henning AN; Good ML; Bosch-Marce M; Maeda T; Liu C; Abdullaev Z; Pack S; Palmer DC; Stroncek DF; Ito F; Flomerfelt FA; Kruhlak MJ; Restifo NP
Cell Rep; 2018 Mar; 22(12):3175-3190. PubMed ID: 29562175
[TBL] [Abstract][Full Text] [Related]
17. Natural Killer Cells Generated From Human Induced Pluripotent Stem Cells Mature to CD56
Euchner J; Sprissler J; Cathomen T; Fürst D; Schrezenmeier H; Debatin KM; Schwarz K; Felgentreff K
Front Immunol; 2021; 12():640672. PubMed ID: 34017328
[TBL] [Abstract][Full Text] [Related]
18. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
[TBL] [Abstract][Full Text] [Related]
19. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation.
Nishimura T; Kaneko S; Kawana-Tachikawa A; Tajima Y; Goto H; Zhu D; Nakayama-Hosoya K; Iriguchi S; Uemura Y; Shimizu T; Takayama N; Yamada D; Nishimura K; Ohtaka M; Watanabe N; Takahashi S; Iwamoto A; Koseki H; Nakanishi M; Eto K; Nakauchi H
Cell Stem Cell; 2013 Jan; 12(1):114-26. PubMed ID: 23290140
[TBL] [Abstract][Full Text] [Related]
20. Generation of Tumor Antigen-Specific Cytotoxic T Lymphocytes from Pluripotent Stem Cells.
Chen X; Lei F; Wang L; Xiong X; Song J
Methods Mol Biol; 2019; 1884():43-55. PubMed ID: 30465194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
